ciprofloxacin has been researched along with Meningitis, Meningococcal in 26 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Meningitis, Meningococcal: A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epidemics of meningococcal meningitis are common in the "African meningitis belt." | 2.84 | Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial. ( Alcoba, G; Ciglenecki, I; Coldiron, ME; Djibo, A; Grais, RF; Hitchings, M; Langendorf, C; Page, AL, 2017) |
| "Neonates are the most at risk of acute bacterial meningitis." | 1.39 | Bacterial isolates from cerebrospinal fluid of children with suspected acute meningitis in a Nigerian tertiary hospital. ( Egesie, JO; Kashibu, E; Nwadioha, SI; Nwokedi, EO; Onwuezube, I, 2013) |
| "Three cases of recrudescence and relapse of Neisseria meningitidis group B meningitis and septicaemia are reported." | 1.29 | Recrudescence and relapse of meningococcal meningitis and septicaemia. ( Nielsen, PE; Thelle, T; Tvede, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.54) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Hedberg, ST | 1 |
| Fredlund, H | 1 |
| Nicolas, P | 1 |
| Caugant, DA | 1 |
| Olcén, P | 1 |
| Unemo, M | 1 |
| Willerton, L | 1 |
| Lucidarme, J | 1 |
| Walker, A | 1 |
| Lekshmi, A | 1 |
| Clark, SA | 1 |
| Walsh, L | 1 |
| Bai, X | 1 |
| Lee-Jones, L | 1 |
| Borrow, R | 1 |
| Rude, JM | 1 |
| Kortimai, L | 1 |
| Mosoka, F | 1 |
| April, B | 1 |
| Nuha, M | 1 |
| Katawera, V | 1 |
| Nagbe, T | 1 |
| Tamba, A | 1 |
| Desmound, W | 1 |
| Mulbah, R | 1 |
| Pierre, F | 1 |
| Onuche, EM | 1 |
| Chukwudi, JO | 1 |
| Talisuna, A | 1 |
| Yahaya, AA | 1 |
| Rajatonirina, S | 1 |
| Nyenswah, T | 1 |
| Dahn, B | 1 |
| Gasasira, A | 1 |
| Fall, IS | 1 |
| Coldiron, ME | 2 |
| Alcoba, G | 2 |
| Ciglenecki, I | 2 |
| Hitchings, M | 1 |
| Djibo, A | 1 |
| Page, AL | 2 |
| Langendorf, C | 2 |
| Grais, RF | 2 |
| Seib, KL | 1 |
| Jen, FE | 1 |
| Scott, AL | 1 |
| Tan, A | 1 |
| Jennings, MP | 1 |
| Lee, H | 1 |
| Seo, Y | 1 |
| Kim, KH | 1 |
| Lee, K | 1 |
| Choe, KW | 1 |
| Klugman, KP | 1 |
| Izadnegahdar, R | 1 |
| Assao, B | 1 |
| Hitchings, MDT | 1 |
| Mambula, C | 1 |
| Adehossi, E | 1 |
| Sidikou, F | 1 |
| Tassiou, EI | 1 |
| De Lastours, V | 1 |
| Sorhouet-Pereira, C | 1 |
| Efron, A | 1 |
| Gagetti, P | 1 |
| Faccone, D | 1 |
| Regueira, M | 1 |
| Corso, A | 1 |
| Gabastou, JM | 1 |
| Ibarz-Pavón, AB | 1 |
| Nwadioha, SI | 1 |
| Nwokedi, EO | 1 |
| Onwuezube, I | 1 |
| Egesie, JO | 1 |
| Kashibu, E | 1 |
| Biswas, HH | 1 |
| Han, GS | 1 |
| Wendorf, K | 1 |
| Winter, K | 1 |
| Zipprich, J | 1 |
| Perti, T | 1 |
| Martinez, L | 1 |
| Arellano, A | 1 |
| Kyle, JL | 1 |
| Zhang, P | 1 |
| Harriman, K | 1 |
| McMahan, DA | 1 |
| Pitcher, ED | 1 |
| Waldron, MR | 1 |
| Billman, AS | 1 |
| Richards, SM | 1 |
| Pontones, PR | 1 |
| Duwve, JM | 1 |
| Lapadula, G | 1 |
| Viganò, F | 1 |
| Fortuna, P | 1 |
| Dolara, A | 1 |
| Bramati, S | 1 |
| Soria, A | 1 |
| Foresti, S | 1 |
| Gori, A | 1 |
| Gorla, MC | 1 |
| de Paiva, MV | 1 |
| Salgueiro, VC | 1 |
| Lemos, AP | 1 |
| Brandão, AP | 1 |
| Vázquez, JA | 2 |
| Brandileone, MC | 1 |
| Alcalá, B | 1 |
| Salcedo, C | 1 |
| de la Fuente, L | 1 |
| Arreaza, L | 1 |
| Uría, MJ | 1 |
| Abad, R | 1 |
| Enríquez, R | 1 |
| Motgé, M | 1 |
| de Batlle, J | 1 |
| Faye, A | 1 |
| Mariani-Kurkjian, P | 1 |
| Taha, MK | 1 |
| Louzeau, C | 1 |
| Bingen, E | 1 |
| Bourrillon, A | 1 |
| Prasad, K | 1 |
| Karlupia, N | 1 |
| Nielsen, PE | 1 |
| Thelle, T | 1 |
| Tvede, M | 1 |
| Martin, MJ | 1 |
| Hutchinson, NA | 1 |
| Eltringham, IJ | 1 |
| Lee, PY | 1 |
| Birthistle, K | 1 |
| Tsakris, A | 1 |
| Trakatelli, C | 1 |
| Souliou, E | 1 |
| Sofianou, D | 1 |
| Ntoutsou, K | 1 |
| Antoniadis, A | 1 |
| Jones, DM | 1 |
| Gaunt, PN | 2 |
| Lambert, BE | 2 |
| Dworzack, DL | 1 |
| Sanders, CC | 1 |
| Horowitz, EA | 1 |
| Allais, JM | 1 |
| Sookpranee, M | 1 |
| Sanders, WE | 1 |
| Ferraro, FM | 1 |
| Evans, CW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response[NCT02724046] | Phase 4 | 300 participants (Actual) | Interventional | 2017-04-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ciprofloxacin and Meningitis, Meningococcal
| Article | Year |
|---|---|
Prevention of bacterial meningitis: an overview of Cochrane systematic reviews.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Ciprofloxacin; Female; Humans; Male; Meningitis, Meni | 2007 |
3 trials available for ciprofloxacin and Meningitis, Meningococcal
| Article | Year |
|---|---|
Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clinical Protocols; Contact Tracing; Drug Resistance, Bacteria | 2017 |
Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Child; Child | 2018 |
Evaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriers.
Topics: Carrier State; Ciprofloxacin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation | 1988 |
22 other studies available for ciprofloxacin and Meningitis, Meningococcal
| Article | Year |
|---|---|
Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives.
Topics: Africa; Genotype; Humans; Meningitis, Meningococcal; Microbial Sensitivity Tests; Neisseria meningit | 2009 |
Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19).
Topics: Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Drug Resistance, Microbial; England; Humans; Meni | 2021 |
Rapid response to meningococcal disease cluster in Foya district, Lofa County, Liberia January to February 2018.
Topics: Adolescent; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Diseas | 2019 |
Phase variation of DNA methyltransferases and the regulation of virulence and immune evasion in the pathogenic Neisseria.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Ceftazidime; Ciprofloxacin; DNA Methylatio | 2017 |
Continuing risk of meningitis due to Neisseria meningitidis serogroup C in Africa: revised recommendations from a WHO expert consultation.
Topics: Advisory Committees; Africa; Anti-Bacterial Agents; Benin; Burkina Faso; Ciprofloxacin; Epidemics; H | 2017 |
Prevalence and serogroup changes of Neisseria meningitidis in South Korea, 2010-2016.
Topics: Adolescent; Adult; Aged; Ceftriaxone; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacte | 2018 |
Antibiotic prophylaxis-Preventing severe infections and saving lives in poor countries with very high mortality risk.
Topics: Africa South of the Sahara; Antibiotic Prophylaxis; Ciprofloxacin; Humans; Meningitis, Meningococcal | 2018 |
Phenotypic and genotypic characteristics of Neisseria meningitidis disease-causing strains in Argentina, 2010.
Topics: Anti-Infective Agents; Argentina; Ciprofloxacin; Drug Resistance, Bacterial; Genotype; Humans; Menin | 2013 |
Bacterial isolates from cerebrospinal fluid of children with suspected acute meningitis in a Nigerian tertiary hospital.
Topics: Adolescent; Anti-Bacterial Agents; Cefotaxime; Ceftriaxone; Cerebrospinal Fluid; Child; Child, Presc | 2013 |
Notes from the Field: Outbreak of Serogroup B Meningococcal Disease at a University - California, 2016.
Topics: Adolescent; California; Ciprofloxacin; Contact Tracing; Disease Outbreaks; Humans; Meningitis, Menin | 2016 |
Notes from the Field: Expanded Chemoprophylaxis Offered in Response to a Case of Meningococcal Meningitis in an Elementary School - Indiana, 2015.
Topics: Adult; Child; Ciprofloxacin; Contact Tracing; Female; Humans; Indiana; Male; Meningitis, Meningococc | 2016 |
Imported ciprofloxacin-resistant Neisseria meningitidis.
Topics: Adult; Ciprofloxacin; Communicable Diseases, Emerging; Contact Tracing; Drug Resistance, Bacterial; | 2009 |
Antimicrobial susceptibility of Neisseria meningitidis strains isolated from meningitis cases in Brazil from 2006 to 2008.
Topics: Adolescent; Adult; Anti-Bacterial Agents; beta-Lactams; Brazil; Child; Child, Preschool; Chloramphen | 2011 |
Neisseria meningitidis showing decreased susceptibility to ciprofloxacin: first report in Spain.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Infant; Male; Meningitis, | 2004 |
[Clinical aspects and outcome of meningococcal disease due to Neisseria meningitidis of serogroup W135 in 5 children].
Topics: Anti-Bacterial Agents; Arthritis, Infectious; Cefotaxime; Child; Child, Preschool; Ciprofloxacin; Fe | 2005 |
Recrudescence and relapse of meningococcal meningitis and septicaemia.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacteremia; Child, Preschool; Chloramphenicol; Ciproflo | 1995 |
Secondary prevention of meningococcal disease. Ceftriaxone or ciprofloxacin should be considered as first line prophylaxis.
Topics: Ceftriaxone; Ciprofloxacin; Humans; Meningitis, Meningococcal; Meningococcal Infections | 1996 |
Advice for travelers.
Topics: Anti-Infective Agents; Antidiarrheals; Bacterial Vaccines; Cholera; Ciprofloxacin; Diarrhea; Diphthe | 1998 |
Failures of rifampicin and ciprofloxacin to eradicate a susceptible meningococcal isolate from a close contact of a fatal case.
Topics: Adolescent; Anti-Infective Agents; Antibiotic Prophylaxis; Antibiotics, Antitubercular; Ciprofloxaci | 2001 |
Chemoprophylaxis of meningitis.
Topics: Ciprofloxacin; Humans; Meningitis, Haemophilus; Meningitis, Meningococcal; Rifampin; Vaccination | 1991 |
Single dose ciprofloxacin for the eradication of pharyngeal carriage of Neisseria meningitidis.
Topics: Carrier State; Ciprofloxacin; Half-Life; Humans; Meningitis, Meningococcal; Meningococcal Infections | 1988 |
A description of the outbreak of meningitis in HMS Raleigh in February 1987.
Topics: Adolescent; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Humans; Male; Meningitis, | 1988 |